Multilayered polymer structure for medical products

Information

  • Patent Grant
  • 6361843
  • Patent Number
    6,361,843
  • Date Filed
    Thursday, June 29, 2000
    24 years ago
  • Date Issued
    Tuesday, March 26, 2002
    22 years ago
Abstract
The present invention provides a multiple layer structure (10) for fabricating medical products. The layer structure (10) has a core layer (14) of an ethylene vinyl alcohol copolymer having an ethylene content of about 25-45 mole percent, a solution contact layer of a polyolefin positioned on a first side of the core layer, an outer layer (12) positioned on a second side of the core layer opposite the solution contact layer (16), the outer layer (12) being selected from the group consisting of polyamides, polyesters and polyolefins; two tie layers (18)—one of each adhered to the first and second sides of the core layer (14) and positioned between the solution contact layer (16) and the core layer (14) and between the outer layer (12) and the core layer (14), and wherein the structure (10) is produced in a cast coextrusion process.
Description




TECHNICAL FIELD




The present invention relates generally to multilayered polymeric structures for fabricating medical grade products and more specifically five-layered structures for fabricating medical solution containers and medical tubings.




BACKGROUND PRIOR ART




In the medical field, where beneficial agents are collected, processed and stored in containers, transported, and ultimately delivered through tubes by infusion to patients to achieve therapeutic effects, materials which are used to fabricate the containers must have a unique combination of properties. For example, in order to visually inspect solutions for particulate contaminants, the container must be optically transparent. To infuse a solution from a container by collapsing the container walls, without introducing air into the container, the material which forms the walls must be sufficiently flexible to collapse upon draining. The material must be functional over a wide range of temperatures. The material must be capable of withstanding radiation sterilization without degrading its physical properties. The material must function at low temperatures by maintaining its flexibility and toughness as some medical solutions, and blood products are stored and transported in containers at temperatures such as −25 to −30° C.




A further requirement is to minimize the environmental impact upon the disposal of the article fabricated from the material after its intended use. For those articles that are disposed of in landfills, it is desirable to use as little material as possible and avoid the incorporation of low molecular weight leachable components to construct the article. Further benefits are realized by using a material which may be recycled by thermoplastically reprocessing the post-consumer article into other useful articles.




For those containers that are disposed of through incineration, it is necessary to use a material that minimizes or eliminates entirely the formation of inorganic acids which are environmentally harmful, irritating, and corrosive, or other products which are harmful, irritating, or otherwise objectionable upon incineration.




For ease of manufacture into useful articles, it is desirable that the material be sealable using radio frequency (“RF”) sealing techniques generally at about 27.12 MHz. Therefore, the material should possess sufficient dielectric loss properties to convert the RF energy to thermal energy.




It is also desirable that the material be free from or have a low content of low molecular weight additives such as plasticizers, slip agents, stabilizers and the like which could be released into the medications or biological fluids or tissues, contaminating such substances being stored or processed in such devices.




In many medical product applications, it is desirable to provide a multilayered structure that provides a barrier to the passage of oxygen, carbon dioxide, and water. For medical solutions that are packaged having a desired concentration of a drug or solute, the barrier to water helps maintain this concentration by preventing water from escaping from the container. In solutions that have a buffer to prevent pH changes, such as a commonly used sodium bicarbonate buffer, the barrier to carbon dioxide helps maintain the buffer by preventing carbon dioxide from escaping from the container. For medical solutions containing labile species, the oxygen barrier helps prevent the ingress of oxygen which can oxidize proteins or amino acids rendering the solution ineffective for its intended purpose.




Ethylene vinyl alcohol (EVOH) is known for use as an oxygen barrier in multilayer films. One commercially available EVOH layered structure is sold by Barrier Film Corporation under the product designation BF-405 for thermoforming into food packaging. It is believed that the BF-405 film has an outer layer of nylon, a core layer of EVOH and an inner layer of a metallocene-catalyzed ultra-low density polyethylene. These layers are formed into a layered structure or film by a blown film process. This film has an oxygen transmission rate, for a film 2.6 mils in thickness, of 0.05 cc/100 sq.in./24 hrs.




The BF-405 film is unacceptable for medical applications as slip agents must be used during the processing of the film. Such slip agents include low molecular weight components that are soluble in water and are capable of leaching out into the medical solution which it contacts. Thus, if such film were constructed into a medical container and filled with a medical solution, it would likely lead to an unacceptably high extractable content in the contained medical solution.




There are numerous U.S. patents that disclose EVOH barrier films. For example, U.S. Pat. No. 4,254,169 provides barrier films having layers of EVOH and polyolefins. The '169 Patent discloses an adhesive for bonding the EVOH to polyolefins which includes a high density polyethylene grafted with a fused-ring carboxylic acid anhydride blended with an unmodified polyolefin. (Col. 2, line 65-col. 3, line 21). In many of the examples, the '169 Patent discloses adding a slip agent to make the outer surface of the films more slippery. (See Tables I and II and col. 5, lines 35-37).




U.S. Pat. No. 4,397,916 discloses multilayered EVOH structures in which the EVOH is attached to other layers such as polyolefins by a layer of a graft-modified ethylene resin grafted with a carboxylic acid or a functional derivative thereof. The '916 Patent also provides for attaching nitrogen containing polymers such as nylons to polyolefins with the graft modified ethylene resins. The '916 Patent does not discuss limiting low molecular weight additives to reduce the amount of extractables. In fact the '916 encourages the use of slip agents, lubricants, pigments, dyes and fillers (Col. 6, lines 38-42) which could have a deleterious impact on the amount of extractables and on the optical transparency of the polymer blend.




U.S. Pat. No. 5,164,258 discloses a multilayered structure containing EVOH as a barrier layer sandwiched between two layers of polyolefins. The polyolefin layers are intended to facilitate the escape of moisture which becomes absorbed in the barrier layer during a steam sterilization process. The polyolefin layers are attached to the EVOH layer with, for example, a maleic anhydride graft-modified polyethylene adhesive. The '258 Patent discloses increasing the WVTR of one of the polyolefin layers by adding organic and inorganic fillers to the layer. (Col. 4, lines 22-59). These fillers are likely to render the multilayered structure optically opaque.




The present invention is provided to solve these and other problems.




SUMMARY OF THE INVENTION




The present invention provides multilayered, flexible, barrier structures that are suitable for forming medical products. The multiple layer structure comprises




(I) a core layer of a vinyl alcohol copolymer, such as ethylene vinyl alcohol (EVOH), having an ethylene content of from 25-45 mole percent;




(II) a solution contact layer of a polyolefin positioned on a first side of the core layer;




(III) an outer layer positioned on a second side of the core layer opposite the solution contact layer, the outer layer being selected from the group consisting of polyamides, polyesters and polyolefins;




(IV) a tie layer adhered to each of the first and second sides of the core layer and positioned between the solution contact layer and the core layer and between the outer layer and the core layer; and




wherein the structure has a low molecular weight water soluble fraction of the composition of less than 1.0 part per thousand (ppt).




It is also preferred that the multilayered structure have the following physical properties: a mechanical modulus as measured by ASTM D 638 of less than 50,000 psi, more preferably less than 40,000 psi and most preferably from 35,000-40,000 or any range or combination of ranges therein. When fabricated into containers and used to store medical liquids, the total organic carbon that leaches out from the layered structure to the solution is less than 1.0 ppt, more preferably less than 100 ppm and most preferably less than 10 ppm. Preferably the layered structure has an oxygen permeability of less than 0.2 cc/100 sq.in./24 hrs.




Preferably the layered structure is formed using a cast coextrusion process that obviates the needs for slip agents and other low molecular weight additives.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

shows a cross-sectional view of a five layered film structure of the present invention;





FIG. 2

shows another embodiment of the present invention; and





FIG. 3

shows yet another embodiment of the present invention.











DETAILED DESCRIPTION




While this invention is susceptible of embodiments in many different forms, and will herein be described in detail, preferred embodiments of the invention are disclosed with the understanding that the present disclosure is to be considered as exemplifications of the principles of the invention and are not intended to limit the broad aspects of the invention to the embodiments illustrated.




According to the present invention, multiple layered film structures are provided which meet the requirements set forth above.





FIG. 1

shows a five layered film structure


10


having an outer layer


12


, a core layer


14


, an inner or solution contact layer


16


and two tie layers


18


. One of each of the tie layers


18


is located between the core layer


14


and the outer layer


12


and the inner layer


16


and the core layer


14


.




The core layer


14


is an ethylene vinyl alcohol copolymer having an ethylene content of from about 25-45 mole percent (ethylene incorporated, as specified in EVALCA product literature). Kuraray Company, Ltd. produces EVOH copolymers under the tradename EVAL® which have about 25-45 mole percent of ethylene, and a melting point of about 150-195° C. Most preferably the EVOH has a ethylene content of 32 mole percent.




The outer layer preferably is a polyamide, polyester, polyolefin or other material that aids in the escape of water away from the core layer. Acceptable polyamides include those that result from a ring-opening reaction of lactams having from 4-12 carbons. This group of polyamides therefore includes nylon 6, nylon 10 and nylon 12. Most preferably, the outer layer is a nylon 12.




Acceptable polyamides also include aliphatic polyamides resulting from the condensation reaction of di-amines having a carbon number within a range of 2-13, aliphatic polyamides resulting from a condensation reaction of di-acids having a carbon number within a range of 2-13, polyamides resulting from the condensation reaction of dimer fatty acids, and amide containing copolymers. Thus, suitable aliphatic polyamides include, for example, nylon 66, nylon 6,10 and dimer fatty acid polyamides.




Suitable polyesters for the outer layer include polycondensation products of di-or polycarboxylic acids and di or poly hydroxy alcohols or alkylene oxides. Preferably, the polyesters are a condensation product of ethylene glycol and a saturated carboxylic acid such as ortho or isophthalic acids and adipic acid. More preferably the polyesters include polyethyleneterphthalates produced by condensation of ethylene glycol and terephthalic acid; polybutyleneterephthalates produced by a condensations of 1,4-butanediol and terephthalic acid; and polyethyleneterephthalate copolymers and polybutyleneterephthalate copolymers which have a third component of an acid component such as phthalic acid, isophthalic acid, sebacic acid, adipic acid, azelaic acid, glutaric acid, succinic acid, oxalic acid, etc.; and a diol component such as 1,4-cyclohexanedimethanol, diethyleneglycol, propyleneglycol, etc. and blended mixtures thereof.




Suitable polyolefins for the outer layer are the same as those specified for the inner layer set forth below. Preferably a polypropylene is used.




It is well known that the oxygen barrier properties of EVOH are adversely impacted upon exposure to water. Thus, it is important to keep the core layer dry. To this end, the outer layer should assist in the removal of water that makes its way to the core layer through the inner layer or otherwise to maintain the oxygen barrier properties of the core layer.




The inner layer is preferably selected from homopolymers and copolymers of polyolefins. Suitable polyolefins are selected from the group consisting of homopolymers and copolymers of alpha-olefins containing from 2 to about 20 carbon atoms, and more preferably from 2 to about 10 carbons. Therefore, suitable polyolefins include polymers and copolymers of propylene, ethylene, butene-1, pentene-1, hexene-1, heptene-1, octene-1, nonene-1 and decene-1. Suitable polyolefins further include lower alkyl and lower alkene acrylates and acetates and ionomers thereof. The term “lower alkyl” means alkyl groups having 1-5 carbon atoms such as ethyl, methyl, butyl and pentyl. The term “ionomer” is used herein to refer to metal salts of the acrylic acid copolymers having pendent carboxylate groups associated with monovalent or divalent cations such as zinc or sodium.




Most preferably, the inner layer is selected from ethylene α-olefin copolymers especially ethylene-butene-1 copolymers which are commonly referred to as ultra-low density polyethylenes (ULDPE). Preferably the ethylene α-olefin copolymers are produced using metallocene catalyst systems. Such catalysts are said to be “single site” catalysts because they have a single, sterically and electronically equivalent catalyst position as opposed to the Ziegler-Natta type catalysts which are known to have a mixture of catalysts sites. Such metallocene catalyzed ethylene α-olefins are sold by Dow under the tradename AFFINITY, and by Exxon under the tradename EXACT. The ethylene α-olefins preferably have a density from 0.880-0.910 g/cc.




Suitable tie layers include modified polyolefins blended with unmodified polyolefins. The modified polyolefins are typically polyethylene or polyethylene copolymers. The polyethylenes can be ULDPE, low density (LDPE), linear low density (LLDPE), medium density polyethylene (MDPE), and high density polyethylenes (HDPE). The modified polyethylenes may have a density from 0.850-0.95 g/cc.




The polyethylene may be modified by grafting with carboxylic acids, and carboxylic anhydrides. Suitable grafting monomers include, for example, maleic acid, fumaric acid, itaconic acid, citraconic acid, allylsuccinic acid, cyclohex-4-ene-1,2-dicarboxylic acid, 4-methylcyclohex-4-ene-1,2-dicarboxylic acid, bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid, x-methylbicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid, maleic anhydride, itaconic anhydride, citraconic anhyride, allylsuccinic anhydride, citraconic anhydride, allylsuccinic anhydride, cyclohex-4-ene-1,2-dicarboxylic anhydride, 4-methylcyclohex-4-ene-1,2-dicarboxylic anhydride, bicyclo[2.2.1]hept-5-ene2,3-dicarboxylic anhydride, and x-methylbicyclo[2.2.1]hept-5-ene-2,2-dicarboxylic anhydride.




Examples of other grafting monomers include C


1


-C


8


alkyl esters or glycidyl ester derivatives of unsaturated carboxylic acids such as methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, butyl acrylate, butyl methacrylate, glycidyl acrylate, glycidal methacrylate, monoethyl maleate, diethyl maleate, monomethyl maleate, diethyl maleate, monomethyl fumarate, dimethyl fumarate, monomethyl itaconate, and diethylitaconate; amide derivatives of unsaturated carboxylic acids such as acrylamide, methacrylamide, maleicmonoamide, maleic diamide, maleic N-monoethylamide, maleic N,N-dietylamide, maleic N-monobutylamide, maleic N,N dibutylamide, fumaric monoamide, fumaric diamide, fumaric N-monoethylamide, fumaric N,N-diethylamide, fumaric N-monobutylamide and fumaric N,N-dibutylamide; imide derivatives of unsaturated carboxylic acids such as maleimide, N-butymaleimide and N-phenylmaleimide; and metal salts of unsaturated carboxylic acids such as sodium acrylate, sodium methacrylate, potassium acrylate and potassium methacrylate. More preferably, the polyolefin is modified by a fused ring carboxylic anhydride and most preferably a maleic anhydride.




The unmodified polyolefins can be selected from the group consisting of ULDPE, LLDPE, MDPE, HDPE and polyethylene copolymers with vinyl acetate and acrylic acid. Suitable modified polyolefin blends are sold, for example, by DuPont under the tradename BYNEL®, by Chemplex Company under the tradename PLEXAR®, and by Quantum Chemical Co. under the tradename PREXAR.




As can be seen in

FIG. 1

, the preferred multilayered structure is asymmetrical about the core layer


14


. That is to say, the solution contact layer


16


is thicker than the outer layer


12


. It is well known that EVOH is hygroscopic. As the EVOH absorbs water its oxygen barrier properties are significantly reduced. The preferred structure


10


provides a relatively thin outer layer of a polyamide that assists in the escape of water away from the core layer


14


. The solution contact layer


16


is a relatively thick layer of a polyolefin which has good water vapor barrier properties and serves to protect the core layer


14


from the ingress of water.




The relative thicknesses of the layers of the structure


10


is as follows: the core layer should have a thickness from 0.2-2.5 mil, more preferably from 0.7-1.3 mil or any range or combination of ranges therein. The outer layer


12


preferably has a thickness from 0.2-2.0 mil and more preferably 0.4-0.8 mil, or any range or combination of ranges therein. The inner layer


16


has a thickness from 3-8 mil and more preferably from 5-7 mil or any range or combination of ranges therein. The tie layers


18


preferably have a thickness from 0.2-1.2 mils and more preferably 0.6-0.8 mils. Thus, the overall thickness of the layered structure will be from 3.8 mils-14.9 mils.





FIG. 2

shows an alternative embodiment having seven layers. This embodiment is the same as that in

FIG. 1

with the exception that the solution contact layer


16


is divided into three sublayers


16




a, b


and


c.


Preferably the centrally disposed sublayer


16




b


of the solution contact


16


has a lower WVTR than its flanking sublayers


16




a


and


16




c.


Most preferably sublayers


16




a


and


16




c


are metallocene-catalyzed ULDPE and the central sublayer


16




b


is a metallocene-catalyzed low-density polyethylene. Preferably the flanking solution contact sublayers


16




a


and


16




c


have thicknesses of about 1 to 7 times, more preferably 2-6 times and most preferably 5 times thicker than the central sublayer


16




b.


Preferably the flanking solution contact sublayers


16




a


and


16




c


will have a thickness of from about 1-5 mils and most preferably 2.5 mils and the central solution contact layer


16




b


will have a thickness of about 0.2-1 mils and most preferably 0.5 mils.





FIG. 3

shows another alternative embodiment that is the same in all respects to the multilayered structure of

FIG. 1

with the exception that the core layer


14


comprises a plurality of thin core sublayers. Preferably there are anywhere from 2-10 core sublayers. It may also be desirable to incorporate tie sublayers in between each of the core sublayers. The tie sublayers may be selected from those set forth above for bonding the inner and outer layers to the core layer.




The layered structures of the present invention are well suited for fabricating medical containers as they can be fabricated into containers and store medical solutions for extended periods of time without having large quantities of low molecular weight components migrating from the layered structure to the contained solution. For a 450 cm


2


surface area container containing 250 ml of saline for seven days, preferably, the quantity of low molecular weight additives, as measured by total organic carbon (TOC), will be less than 1.0 ppt, more preferably less than 100 ppm and most preferably less than 10 ppm.




The above layers may be processed into a layered structure by standard techniques well known to those of ordinary skill in the art and including cast coextrusion, coextrusion coating, or other acceptable process. For ease of manufacture into useful articles, it is desirable that the layered structure can be welded using radio frequency (“RF”) welding techniques generally at about 27.12 MHz. Therefore, the material should possess sufficient dielectric loss properties to convert the RF energy to thermal energy. Preferably, the outer layer


12


of the layered structure will have a dielectric loss of greater than 0.05 at frequencies within the range of 1-60 MHz within a temperature range of ambient to 250° C.




Preferably, the layered structure is fabricated into films using a cast coextrusion process. The process should be essentially free of slip agents and other low molecular weight additives that may increase the extractables to an unacceptable level.




An illustrative, non-limiting example of the present multilayered structures is set out below. Numerous other examples can readily be envisioned in light of the guiding principles and teachings contained herein. The example given herein is intended to illustrate the invention and not in any sense to limit the manner in which the invention can be practiced.




EXAMPLE




A five-layered structure was coextruded in accordance with the teachings of the present invention. The five-layered structure had an outer layer of nylon 12 (EMS America Grilon-Grilamid L20) having a thickness of 0.6 mil, a tie layer (BYNEL® 4206 (DuPont)) having a thickness of 0.7 mil, a core layer of EVOH (EVAL® EVOH LC-F101AZ) having a thickness of 1.0 mil, and a ULDPE (Dow AFFINITY® PL1880) having a thickness of 6.0 mil. The structure was radiation sterilized using a cobalt source at a dosage of 40-45 kGys.




The table below shows how the oxygen permeability of the structure depends on temperature. The oxygen permeability was measured using a MoCon tester (Modern Controls, Minneapolis, Minn.). The test chamber had a relative humidity of 75% on the O


2


side and a 90% relative humidity on the N


2


side to replicate a solution filled container in a high humidity environment.




















O


2


PERMEABILITY







TEMPERATURE ° C.




cc/100 in


2


/day



























8




0.002







15




0.003







22




0.018







30




0.046







40




0.156















The water vapor transmission rate was also measured at 23° C. and at a humidity gradient of 90% yielding a WVTR of 0.035 g H


2


O/100 in


2


/day.




It will be understood that the invention may be embodied in other specific forms without departing from the spirit or central characteristics thereof. The present example and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and the invention is not to be limited to the details given herein.



Claims
  • 1. A multiple layer structure for fabricating medical products comprising:a core layer of an ethylene vinyl alcohol copolymer having an ethylene content of about 25-45 mole percent; a solution contact layer of a polyolefin positioned on a first side of the core layer; an outer layer positioned on a second side of the core layer opposite the solution contact layer, the outer layer being selected from the group consisting of polyamides, polyesters and polyolefins; two tie layers, one of each adhered to the first and second sides of the core layer and positioned between the solution contact layer and the core layer and between the outer layer and the core layer; and wherein the structure is produced in a cast coextrusion process.
  • 2. The structure of claim 1 wherein the polyamide is selected from aliphatic polyamides resulting from the condensation reaction of di-amines having a carbon number within a range of 2-13, aliphatic polyamides resulting from a condensation reaction of di-acids having a carbon number within a range of 2-13, polyamides resulting from the condensation reaction of dimer fatty acids, and amide containing copolymers.
  • 3. The structure of claim 1 wherein the polyamide is selected from the group of polyamides produced in a ring-opening reaction of lactams having from 4-12 carbons.
  • 4. The structure of claim 3 wherein the polyamide is nylon 12.
  • 5. The structure of claim 1 wherein the polyolefin of the solution contact layer is selected from the group consisting of homopolymers and copolymers of alpha-olefins containing from 2 to about 20 carbon atoms.
  • 6. The structure of claim 5 wherein the polyolefin of the solution contact layer is a homopolymer or a copolymer of an alpha-olefin having from 2 to about 10 carbons.
  • 7. The structure of claim 6 wherein the polyolefin is selected from the group consisting of ethylene copolymers, and butene-1 copolymers.
  • 8. The structure of claim 7 wherein the ethylene copolymer of the solution contact layer is an ethylene-butene-1 copolymer.
  • 9. The structure of claim 8 wherein the ethylene copolymer of the solution contact layer is produced using a metallocene catalyst.
  • 10. The structure of claim 1 wherein the tie layer is a polyolefin polymer or copolymer blended with a polyethylene copolymer grafted with a carboxylic acid anhydride or a carboxylic acid.
  • 11. The structure of claim 10 wherein the carboxylic acid anhydride is an unsaturated flised ring carboxylic acid anhydride.
  • 12. The structure of claim 11 wherein the carboxylic acid anhydride is a maleic anhydride.
  • 13. The structure of claim 1 wherein the low molecular weight water soluble fraction of the structure is less than 1.0 ppt as measured for a container having a surface area of 450 cm2 and containing 250 ml of saline solution.
  • 14. The structure of claim 1 wherein the low molecular weight water soluble fraction of the structure is less than 100 ppm as measured for a container having a surface area of 450 cm2 and containing 250 ml of saline solution.
  • 15. The structure of claim 1 wherein the low molecular weight water soluble fraction of the structure is less than 10 ppm as measured for a container having a surface area of 450 cm2 and containing 250 ml of saline solution.
  • 16. The structure of claim 1 wherein the solution contact layer is from about 3-8 mils thick, the core layer is from about 0.2-2.5 mils thick, the outer layer is from about 0.2-2.0 mils thick, and the tie layers are from 0.2-1.2 mils thick to define an asymmetrical structure about the core layer.
RELATED APPLICATIONS

This is a continuation of U.S. patent application Ser. No. 08/934,924 filed Sep. 22, 1997 now U.S. Pat. No. 6,083,587 which is incorporated herein by reference and made a part hereof.

US Referenced Citations (168)
Number Name Date Kind
3536693 Schrader et al. Oct 1970 A
3955040 Schirmer May 1976 A
4064296 Bornstein et al. Dec 1977 A
4082854 Yamada et al. Apr 1978 A
4082877 Shadle Apr 1978 A
4095012 Schirmer Jun 1978 A
4197326 Wakamatsu et al. Apr 1980 A
4212956 Katsura Jul 1980 A
4212966 McClain Jul 1980 A
4220684 Olson Sep 1980 A
4233367 Ticknor et al. Nov 1980 A
4239826 Knott, II et al. Dec 1980 A
4254169 Schroeder Mar 1981 A
4255490 Katsura Mar 1981 A
4281045 Sumi et al. Jul 1981 A
4284674 Sheptak Aug 1981 A
4322480 Tuller et al. Mar 1982 A
4349644 Iwanami et al. Sep 1982 A
4350797 Marzola et al. Sep 1982 A
4355721 Knott, II et al. Oct 1982 A
4361628 Krueger et al. Nov 1982 A
4397916 Nagano Aug 1983 A
4397917 Chi et al. Aug 1983 A
4405667 Christensen et al. Sep 1983 A
4407873 Christensen et al. Oct 1983 A
4445550 Davis et al. May 1984 A
4457960 Newsome Jul 1984 A
4460632 Adur et al. Jul 1984 A
4464438 Lu Aug 1984 A
4465487 Nakamura et al. Aug 1984 A
4468427 Degrassi et al. Aug 1984 A
4486497 Mizutani Dec 1984 A
4501798 Koschak et al. Feb 1985 A
4528219 Yamada et al. Jul 1985 A
4536409 Farrell et al. Aug 1985 A
4536532 Miller et al. Aug 1985 A
4551371 Eckstein Nov 1985 A
4552714 Kreuger et al. Nov 1985 A
4552716 Habich Nov 1985 A
4552801 Odozynski et al. Nov 1985 A
4561110 Herbert Dec 1985 A
4561920 Foster Dec 1985 A
4562118 Maruhashi et al. Dec 1985 A
4572854 Dallmann et al. Feb 1986 A
4588177 White May 1986 A
4588648 Krueger et al. May 1986 A
4590131 Yazaki et al. May 1986 A
4605576 Jabarin Aug 1986 A
4615922 Newsome et al. Oct 1986 A
4615926 Hsu et al. Oct 1986 A
4617240 Krueger et al. Oct 1986 A
4636412 Field Jan 1987 A
4639398 Bergstrom Jan 1987 A
4645695 Negi et al. Feb 1987 A
4647483 Tse et al. Mar 1987 A
4650452 Jensen Mar 1987 A
4650721 Aschcraft et al. Mar 1987 A
4668571 Moriarty, Jr. May 1987 A
4672087 Miller et al. Jun 1987 A
4677017 DeAntonis et al. Jun 1987 A
4684573 Mueller et al. Aug 1987 A
4684576 Tabor et al. Aug 1987 A
4695491 Kondo et al. Sep 1987 A
4702966 Farrell et al. Oct 1987 A
4705708 Briggs et al. Nov 1987 A
4724185 Shah Feb 1988 A
4726984 Shah Feb 1988 A
4729476 Lulham et al. Mar 1988 A
4731266 Bonnebat et al. Mar 1988 A
4746562 Fant May 1988 A
4755419 Shah Jul 1988 A
4758463 Vicik et al. Jul 1988 A
4767651 Starczewski et al. Aug 1988 A
4770944 Farrell et al. Sep 1988 A
4789575 Gibbons et al. Dec 1988 A
4808482 Benge et al. Feb 1989 A
4818592 Ossian Apr 1989 A
4828915 Schroeder et al. May 1989 A
4839235 Shah Jun 1989 A
4842947 Jachec et al. Jun 1989 A
4857399 Vicik Aug 1989 A
4857408 Vivik Aug 1989 A
4871410 Bonnebat et al. Oct 1989 A
4875587 Lulham et al. Oct 1989 A
4877662 Yazaki et al. Oct 1989 A
4881649 Hsu et al. Nov 1989 A
4883696 Iwanami et al. Nov 1989 A
4902558 Henricksen Feb 1990 A
4911963 Lustig et al. Mar 1990 A
4911979 Nishimoto et al. Mar 1990 A
4917925 Loretti et al. Apr 1990 A
4929479 Shishido et al. May 1990 A
4950515 Mason et al. Aug 1990 A
RE33376 Gibbons et al. Oct 1990 E
4963426 Nishimoto et al. Oct 1990 A
4971864 McCord Nov 1990 A
4983432 Bissot Jan 1991 A
5004647 Shah Apr 1991 A
5039565 Dyerup Aug 1991 A
5040583 Lin et al. Aug 1991 A
5049449 Ofstein Sep 1991 A
5053259 Vicik Oct 1991 A
5077109 Lustig et al. Dec 1991 A
5085816 McCord Feb 1992 A
5108807 Tucker Apr 1992 A
5126198 Schinkel et al. Jun 1992 A
5129894 Sommermeyer et al. Jul 1992 A
5132149 Kotani et al. Jul 1992 A
5137763 Bauer et al. Aug 1992 A
5141795 Kai et al. Aug 1992 A
5143570 Freedmam Sep 1992 A
5156921 Lin et al. Oct 1992 A
5164258 Shida et al. Nov 1992 A
5169697 Langley et al. Dec 1992 A
5171640 Wirth Dec 1992 A
5183706 Bekele Feb 1993 A
5186782 Freedman Feb 1993 A
5206688 Onishi et al. Apr 1993 A
5208082 Choue May 1993 A
5208094 Sun May 1993 A
5232754 Waugh Aug 1993 A
5234731 Ferguson Aug 1993 A
RE34537 Deyrup Feb 1994 E
RE34546 Deyrup Feb 1994 E
5283128 Wilhoit Feb 1994 A
5292590 Lin et al. Mar 1994 A
5300354 Harita et al. Apr 1994 A
5318829 Tada et al. Jun 1994 A
5346732 Lai et al. Sep 1994 A
5348771 Lee et al. Sep 1994 A
5360670 Yonezu et al. Nov 1994 A
5362532 Famili et al. Nov 1994 A
5370937 Lee et al. Dec 1994 A
5372669 Freedman Dec 1994 A
5372880 Lee et al. Dec 1994 A
5374459 Mumpower et al. Dec 1994 A
5380586 Knoerzer et al. Jan 1995 A
5407713 Wilfong et al. Apr 1995 A
5434007 Yeh Jul 1995 A
5434010 Smith et al. Jul 1995 A
5462807 Halle et al. Oct 1995 A
5463375 Bauer Oct 1995 A
5464691 Gardiner et al. Nov 1995 A
5466498 Fortoni et al. Nov 1995 A
5472792 Tsurutani et al. Dec 1995 A
5482770 Bekele Jan 1996 A
5482771 Shah Jan 1996 A
5487940 Bianchini et al. Jan 1996 A
5489478 Audry et al. Feb 1996 A
5491009 Bekele Feb 1996 A
5491011 Pezzoli et al. Feb 1996 A
RE35285 Quacquarella et al. Jun 1996 E
5534351 Pearson et al. Jul 1996 A
5547764 Blais et al. Aug 1996 A
5547765 Degrassi et al. Aug 1996 A
5552002 Farrell et al. Sep 1996 A
5552212 Knoerzer Sep 1996 A
5558930 DiPoto Sep 1996 A
5559176 Namba et al. Sep 1996 A
5562996 Kuriu et al. Oct 1996 A
5604042 Bianchini et al. Feb 1997 A
5604043 Ahlgren Feb 1997 A
5618599 Nulman et al. Apr 1997 A
5620758 Babrowski Apr 1997 A
5628629 Mitani et al. May 1997 A
5629059 Desai et al. May 1997 A
5645906 Park et al. Jul 1997 A
6083587 Smith Jul 2000 A
Foreign Referenced Citations (7)
Number Date Country
0 230 344 Jul 1987 EP
0 451 977 Oct 1991 EP
0 465 428 Jan 1992 EP
0 504 808 Sep 1992 EP
0 561 428 Sep 1993 EP
0 698 487 Feb 1996 EP
2 131 739 Jun 1984 GB
Continuations (1)
Number Date Country
Parent 08/934924 Sep 1997 US
Child 09/607058 US